PE20081791A1 - Dos derivados ciclicos de oxomorfolina - Google Patents

Dos derivados ciclicos de oxomorfolina

Info

Publication number
PE20081791A1
PE20081791A1 PE2008000381A PE2008000381A PE20081791A1 PE 20081791 A1 PE20081791 A1 PE 20081791A1 PE 2008000381 A PE2008000381 A PE 2008000381A PE 2008000381 A PE2008000381 A PE 2008000381A PE 20081791 A1 PE20081791 A1 PE 20081791A1
Authority
PE
Peru
Prior art keywords
oxazin
oxomorpholin
trifluorophenyl
ona
tetrahydro
Prior art date
Application number
PE2008000381A
Other languages
English (en)
Inventor
Teiji Kimura
Noritaka Kitazawa
Toshihiko Kaneko
Takehiko Miyagawa
Koki Kawano
Mamoru Takaishi
Takeo Sasaki
Eriko Doi
Koichi Ito
Nobuaki Sato
Original Assignee
Eisai Randd Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39716667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20081791(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai Randd Man Co Ltd filed Critical Eisai Randd Man Co Ltd
Publication of PE20081791A1 publication Critical patent/PE20081791A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE OXOMORFOLINA DE FORMULA I, DONDE R1 ES ALQUILO C1-C3; R2 ES H, ALQUILO C1-C3 O R1 Y R2 JUNTO AL CARBONO AL QUE ESTAN UNIDO SON CICLOALQUILO C3-C6; Ar ES FENILO SUSTITUIDO O NO; X ES METILENO SUSTITUIDO O NO; m Y n SON 0-2. SON SELECCIONADOS: (Z)(1R, 6R, 9aR)-3-[3-METOXI-4-(4-METILIMIDAZOL-1-IL)BENCILIDEN]-1-METIL-6-(3,4,5-TRIFLUOROFENIL)TETRAHIDRO-[1,4]OXAZIN[3,4-c][1,4]-OXAZIN-4-ONA; (6R,9aR)-3-[1-[3-METOXI-4-(4-METIL-1H-IMIDAZOL-2-IL)FENIL-(Z)-METILIDEN]-1,1-DIMETIL-6-(3,4,5-TRIFLUOROFENIL)TETRAHIDRO[1,4[OXAZIN[3,4-c][1,4]OXAZIN-4-ONA; ENTRE OTROS. DICHOS COMPUESTOS SON DE UTILIDAD EN EL TRATAMIENTO DE ENFERMEDADES ATRIBUIBLES A AMILOIDE BETA, TALES COMO ALZHEIMER, DEMENCIA SENIL, SINDROME DE DOWN O AMILOIDOSIS
PE2008000381A 2007-02-28 2008-02-26 Dos derivados ciclicos de oxomorfolina PE20081791A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89199707P 2007-02-28 2007-02-28
JP2007049085 2007-02-28

Publications (1)

Publication Number Publication Date
PE20081791A1 true PE20081791A1 (es) 2009-02-07

Family

ID=39716667

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000381A PE20081791A1 (es) 2007-02-28 2008-02-26 Dos derivados ciclicos de oxomorfolina

Country Status (11)

Country Link
US (2) US20080207900A1 (es)
EP (1) EP2125829B1 (es)
JP (1) JP5244096B2 (es)
KR (1) KR20090116704A (es)
CN (1) CN101622258B (es)
AU (1) AU2008221906C1 (es)
CA (1) CA2678100A1 (es)
CL (1) CL2008000582A1 (es)
PE (1) PE20081791A1 (es)
TW (1) TW200848054A (es)
WO (1) WO2008108378A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115990A1 (ja) * 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. シンナミド化合物
KR20100055456A (ko) * 2007-08-31 2010-05-26 에자이 알앤드디 매니지먼트 가부시키가이샤 다환식 화합물
WO2009067493A2 (en) * 2007-11-19 2009-05-28 Envivo Pharmaceuticals, Inc. 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
CA2710477A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
EP2401277A1 (en) 2009-02-26 2012-01-04 Eisai R&D Management Co., Ltd. Salt of tetrahydrotriazolopyridine derivative and crystal thereof
CA2753696A1 (en) 2009-02-26 2010-09-02 Noritaka Kitazawa Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
EP2445878A1 (en) * 2009-06-24 2012-05-02 Boehringer Ingelheim International GmbH New compounds, pharmaceutical composition and methods relating thereto
TW201113269A (en) * 2009-06-24 2011-04-16 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
AU2011227511B2 (en) 2010-03-15 2014-02-20 Amgen Inc. Spiro-tetracyclic ring compounds as Beta - secretase modulators
JP5584352B2 (ja) 2010-03-15 2014-09-03 アムジエン・インコーポレーテツド β−セクレターゼ調節剤としてのアミノ−ジヒドロオキサジン系およびアミノ−ジヒドロチアジン系スピロ化合物ならびにそれらの医学的用途
EP2601197B1 (en) 2010-08-05 2014-06-25 Amgen Inc. Amino-iso-indole, amino-aza-iso-indole, amino-dihydroisoquinoline and amino-benzoxazine compounds as beta-secretase modulators and methods of use
EP2643325A1 (en) 2010-11-23 2013-10-02 Amgen Inc. Spiro-amino-imidazolone and spiro-amino-dihydro-pyrimidinone compounds as beta-secretase modulators and methods of use
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
WO2012112462A1 (en) 2011-02-15 2012-08-23 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
EP2691393B1 (en) 2011-03-31 2016-09-14 Pfizer Inc Novel bicyclic pyridinones
WO2013044092A1 (en) 2011-09-21 2013-03-28 Amgen Inc. Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
US9725469B2 (en) 2012-11-15 2017-08-08 Amgen, Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
EP3253755B1 (en) 2015-02-03 2020-08-26 Pfizer Inc Novel cyclopropabenzofuranyl pyridopyrazinediones
WO2019098256A1 (ja) * 2017-11-16 2019-05-23 株式会社幹細胞&デバイス研究所 デバイス

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1101156A (en) 1965-09-22 1968-01-31 Hickson & Welch Ltd Triazole derivatives and their use as optical whitening agents
FR2314731A1 (fr) 1975-06-19 1977-01-14 Nelson Res & Dev Azacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4508718A (en) 1984-01-16 1985-04-02 Warner-Lambert Company Cardiotonic and antihypertensive oxadiazinone compounds
DE3689506D1 (de) * 1985-10-09 1994-02-17 Shell Int Research Neue Acrylsäureamide.
US4783463A (en) 1985-10-23 1988-11-08 Rorer Pharmaceutical Corporation Pyridyl-pyridazinone and pyridyl-pyrazolinone compounds and their use in the treatment of congestive heart failure
DE3541716A1 (de) 1985-11-26 1987-05-27 Celamerck Gmbh & Co Kg Neue acrylsaeureamide
FI91754C (fi) 1986-12-02 1994-08-10 Tanabe Seiyaku Co Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi
FI902321A0 (fi) 1989-05-19 1990-05-09 Eisai Co Ltd Butensyraderivat.
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
WO1991012237A1 (fr) * 1990-02-08 1991-08-22 Eisai Co., Ltd. Derive de sulfonamide de benzene
AU680870B2 (en) * 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
KR970706242A (ko) 1994-10-04 1997-11-03 후지야마 아키라 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors)
JPH08283219A (ja) 1995-04-07 1996-10-29 Eisai Co Ltd アラルキルアミノアルキルアミド誘導体
US5804577A (en) 1995-09-12 1998-09-08 Hoffmann-La Roche Inc. Cephalosporin derivatives
AU713247B2 (en) 1995-10-19 1999-11-25 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1997043287A1 (en) * 1996-05-10 1997-11-20 Icos Corporation Carboline derivatives
WO1998003166A1 (en) 1996-07-22 1998-01-29 Monsanto Company Thiol sulfonamide metalloprotease inhibitors
US5672612A (en) 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
JP2001508767A (ja) 1996-12-02 2001-07-03 藤沢薬品工業株式会社 5―ht拮抗作用を有するインドール―ウレア誘導体
WO1998043970A1 (en) 1997-03-31 1998-10-08 Takeda Chemical Industries, Ltd. Azole compounds, their production and their use
JP3108997B2 (ja) 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
TW379224B (en) 1997-12-02 2000-01-11 Fujisawa Pharmaceutical Co Urea derivatives
JP2001527083A (ja) 1997-12-31 2001-12-25 ザ・ユニバーシティ・オブ・カンザス 第二級および第三級アミン含有薬剤の水溶性プロドラッグおよびその製造方法
GB9816984D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6235728B1 (en) * 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
WO2000051981A1 (en) * 1999-03-04 2000-09-08 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
US20040087798A1 (en) * 2000-03-14 2004-05-06 Akira Yamada Novel amide compounds
US20010051642A1 (en) * 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CN1257894C (zh) 2000-12-04 2006-05-31 弗·哈夫曼-拉罗切有限公司 作为谷氨酸受体拮抗剂的苯基乙烯基或苯基乙炔基衍生物
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
JP2005503400A (ja) 2001-09-13 2005-02-03 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド サイトカイン媒介病の治療方法
EP1429763B1 (en) 2001-09-14 2007-05-30 Novo Nordisk A/S NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER
AU2002364549B2 (en) 2001-12-10 2007-11-22 Amgen, Inc Vanilloid receptor ligands and their use in treatments
WO2003053912A1 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS
JP2003206280A (ja) 2001-12-28 2003-07-22 Takeda Chem Ind Ltd ビアリール化合物およびその用途
EP1509505A2 (en) 2002-01-23 2005-03-02 Arena Pharmaceuticals, Inc. SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
US20050049267A1 (en) 2002-03-01 2005-03-03 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
DE60335635D1 (de) * 2002-05-22 2011-02-17 Amgen Inc Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen
ES2473581T3 (es) * 2002-05-31 2014-07-07 Proteotech Inc. Compuestos, composiciones y métodos para el tratamiento de amiloidosis y sinucleinopat�as tales como la enfermedad de Alzheimer, la diabetes de tipo 2 y la enfermedad de Parkinson
WO2004002478A1 (en) 2002-06-27 2004-01-08 Elan Pharmaceuticals, Inc. Methods for treating alzheimer's disease using hydroxyethylene compounds containing a heterocyclic amide bond isostere
PL373329A1 (en) 2002-07-12 2005-08-22 Sanofi-Aventis Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
JP2006518738A (ja) 2003-02-12 2006-08-17 トランス テック ファーマ,インコーポレイテッド 治療薬としての置換アゾール誘導体
JP2006522142A (ja) 2003-04-01 2006-09-28 プラス ケミカルズ ベスローテン フェンノートシャップ 非晶質シンバスタチン・カルシウムとその製造方法
EP1628666B1 (en) * 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
AU2004268621C1 (en) * 2003-08-29 2011-08-18 Exelixis, Inc. c-Kit modulators and methods of use
JP4698604B2 (ja) 2003-12-22 2011-06-08 ファイザー・インク バソプレシン・アンタゴニストとしてのトリアゾール誘導体
WO2005072731A1 (en) 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
JP4898458B2 (ja) 2004-02-12 2012-03-14 トランス テック ファーマ,インコーポレイテッド 置換アゾール誘導体、組成物及び使用方法
WO2005087768A1 (en) 2004-03-09 2005-09-22 Merck & Co., Inc. Hiv integrase inhibitors
WO2005115990A1 (ja) 2004-05-26 2005-12-08 Eisai R & D Management Co., Ltd. シンナミド化合物
US20080261952A1 (en) 2004-08-16 2008-10-23 Jason Bloxham Aryl Urea Derivatives for Treating Obesity
CN100577657C (zh) 2004-10-26 2010-01-06 卫材R&D管理有限公司 肉桂酰胺化合物的无定形物
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
US20090270623A1 (en) 2005-11-18 2009-10-29 Naoyuki Shimomura Process for production of cinnamide derivative
WO2007058304A1 (ja) 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. シンナミド化合物の塩またはそれらの溶媒和物
US20070117839A1 (en) * 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
CA2629745A1 (en) 2005-11-24 2007-05-31 Eisai R & D Management Co., Ltd. Morpholine type cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
EA016464B1 (ru) 2006-03-09 2012-05-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Полициклические производные арилимидазола
AR062095A1 (es) * 2006-07-28 2008-10-15 Eisai R&D Man Co Ltd Profarmaco de compuesto cinamida
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
WO2008137102A2 (en) 2007-05-04 2008-11-13 Torreypines Therapeutics, Inc. Methods of modulating amyloid beta and compounds useful therefor
RU2009144998A (ru) 2007-05-07 2011-06-20 Шеринг Корпорейшн (US) Модуляторы гамма-секретазы
CN101675045B (zh) * 2007-05-11 2012-11-28 弗·哈夫曼-拉罗切有限公司 作为β-淀粉样蛋白调节剂的杂芳基苯胺
US8242150B2 (en) 2007-06-13 2012-08-14 Merck Sharp & Dohme Corp. Triazole derivatives for treating alzheimer'S disease and related conditions
EP2185522A1 (en) 2007-08-06 2010-05-19 Schering Corporation Gamma secretase modulators

Also Published As

Publication number Publication date
AU2008221906A1 (en) 2008-09-12
JP5244096B2 (ja) 2013-07-24
TW200848054A (en) 2008-12-16
WO2008108378A3 (en) 2008-12-04
CN101622258B (zh) 2012-06-13
AU2008221906C1 (en) 2012-12-13
EP2125829A2 (en) 2009-12-02
KR20090116704A (ko) 2009-11-11
CL2008000582A1 (es) 2008-06-27
AU2008221906B2 (en) 2012-04-12
CN101622258A (zh) 2010-01-06
WO2008108378A2 (en) 2008-09-12
EP2125829B1 (en) 2013-01-16
JP2010520152A (ja) 2010-06-10
US8008293B2 (en) 2011-08-30
US20080207900A1 (en) 2008-08-28
CA2678100A1 (en) 2008-09-12
US20100113773A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
PE20081791A1 (es) Dos derivados ciclicos de oxomorfolina
DOP2009000232A (es) Metanoisoindoles y dionas de éstos como agentes anti-psicóticos.
MY152386A (en) Substituted 6a,7,8,9-tetrahydropyrido[3,2-e] pyrrolo[1,2-a]pyrazin-6(5h)-ones
AR082154A1 (es) DERIVADOS DE PIRAZOLO[1,5-a]PIRIMIDINA COMO MODULADORES DE IRAK4
PE20120172A1 (es) Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide
PE20110296A1 (es) Compuestos heterociclicos fusionados como moduladores del receptor de orexina
SG195289A1 (en) Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
ECSP024393A (es) Derivados biciclicos sustituidos para el tratamiento del crecimiento celular normal
NZ592642A (en) Tricyclic oxazolidinone antibiotic compounds
PE20070491A1 (es) Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina
CL2010001162A1 (es) Compuestos derivados de octahidropirrolo[3,4-c]pirrol disustituidos, moduladores de orexina; composicion farmaceutica que comprende a dichos compuestos; utiles en trastornos del ciclo sueño-vigilia, trastornos metabolicos, trastornos neurologicos, entre otros
NZ631187A (en) Tricyclic quinoline and quinoxaline derivatives
PE20110777A1 (es) Nuevas lactamas como inhibidores de beta secretasa
NZ590297A (en) 2-Alkylamino-7,8-dihydropteridin-6(5H)-one and 2-alkylamino-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one derivatives
AR078437A1 (es) Derivados de imidazopiridina, procesos de obtencion y composiciones farmaceuticas
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
MX2011013870A (es) Compuestos biciclicos y triciclicos como inhibidores de quinurenina aminotransferasa ii.
PE20120054A1 (es) COMPUESTOS DERIVADOS DE 4,8-DIHIDRO-4,7-METANO-7H-PIRAZOLO[3,4-e][1,3]DIAZEPINA-6(5H)-ONA CON ACTIVIDAD ANTIBACTERIANA
AR084832A1 (es) Derivado cristalino de oxazina
EA201171393A1 (ru) 7-([1,2,4]ТРИАЗОЛО[1,5α]ПИРИДИН-6-ИЛ)-4-(3,4-ДИХЛОРФЕНИЛ)-1,2,3,4-ТЕТРАГИДРОИЗОХИНОЛИН И ЕГО ПРИМЕНЕНИЕ
ES2587745T3 (es) Derivados de imidazo[2,1]tiazol-3-ona útiles como agentes de diagnóstico para la enfermedad de Alzheimer
CO6341621A2 (es) Piperidinas arilamino y heteroarilamino sustituidas como inhibidores de glyt-1
AR071619A1 (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias y composiciones farmaceuticas que los contienen.
WO2008110690A3 (fr) Nouveaux derives indoliques, leurs procedes de preparation et leurs utilisations notamment en tant qu'antibacteriens

Legal Events

Date Code Title Description
FA Abandonment or withdrawal